Yearly Archives: 2015

VGXI Celebrates Opening of the Advanced Biopharmaceuticals International Center of Support

On June 18th, 2015 VGXI celebrated the opening of the Advanced Biopharmaceuticals International Center of Support (ABICS) at their facility in The Woodlands, TX.

ABICS

In response to the recent MERS outbreak, the Texas-based clinical manufacturing organization, VGXI has rapidly mobilized in collaboration with the Korean company GeneOne Life sciences to expedite production and Phase I clinical testing of a DNA based MERS vaccine. Link to the recent press release. As a key player in the international effort to develop the vaccine, the leadership of these companies realized a need to support more opportunities for these kinds of collaborative efforts.

On Thursday, June 18th delegates of the South Korean Ministry of Trade, Industry, and Energy (MOTIE) and leadership for the Korea Biotechnology Industry Organization (KoreaBIO) visited Houston, TX. Recognizing this unique opportunity, VGXI helped to facilitate a Memorandum of Understanding (MOU) between KoreaBIO and the respective Texas Healthcare and Bioscience Institute (THBI) with the intention to promote increased business connections and relationships between the Texas and Korean biotechnology communities.
MOU Signing
Following the signing of the historic MOU, attendees visited the VGXI facility to celebrate the opening of the Advanced Biopharmaceuticals International Center of Support (ABICS). This center will serve as a primary point of contact supporting communications and facilitating interactions for Korean companies seeking business partnerships in the state of Texas.

For more information, contact:
Christy Franco, PhD
Business Development Manager
Email
P: 281-466-3790

Logo_QualityTagline_2014_black_transparent

Innovations Episode Featuring VGXI Aired June 26, 2015 via the Discovery Channel

DMG Productions explores the latest technological breakthroughs in science and technology.

Jupiter, FL (PRWEB) June 22, 2015

Innovations

DMG Productions announced the airing of Innovations with Ed Begley, Jr., on Friday, June 26, 2015, via the Discovery Channel.

The show featured VGXI Inc., a leading contract manufacturer of DNA plasmids known for their cGMP and non-cGMP products, which have passed rigorous international regulatory reviews. Innovations educated on VGXI’s patented manufacturing process and cGMP production facilities.

“Advancements in science and technology are at the forefront of the healthcare community,” said Michele Nehls, Producer for Innovations. “The episode features some of the fundamental products, people, and technologies responsible for enabling better diagnostics and treatment options for patients.”

About Innovations & DMG Productions: Innovations, hosted by award winning actor Ed Begley, Jr., is an information-based series geared toward educating the public on the latest breakthroughs in all areas of society. Featuring practical solutions and important issues facing consumers and professionals alike, Innovations focuses on cutting-edge advancements in everything from health and wellness to global business, renewable energy, and more.

DMG Productions (responsible for creating the Innovations show) includes personnel specialized in various fields from agriculture to medicine, independent films to regional news and more. Our field producers work closely with experts in the field to develop stories. This powerful force enables us to consistently produce commercial-free, educational programming that both viewers and networks depend on.

Full press release available here:  PRWeb

Congressman Kevin Brady visited VGXI on May 4, 2015

VGXI to support expedited development and scale-up of multiple vaccine candidates to treat Ebola through a DARPA funded collaboration.

Brady-050415

US Congressman Kevin Brady visited the VGXI manufacturing facility in The Woodlands, TX on May 4th, 2015 to tour the production plant and provide a statement on the impact of this work and the DNA-based therapeutics being produced at VGXI. Leadership from Inovio Pharmaceuticals and GeneOne Life Sciences will also be present to provide a brief overview of the collaboration and the scope of the DARPA funded project.

News Link

How these therapies are different from many other Ebola vaccines in development:

  • The vaccine contains DNA only – no virus particles or proteins will be manufactured
  • The vaccine can be used to treat to patients who have already been exposed to the virus
  • DNA vaccine production can be scaled-up very rapidly in case of an outbreak

Full details of the DARPA funding and development of new treatments for Ebola can be found in the following press release:
Inovio Pharmaceuticals Selected by DARPA to Lead a $45 Million Program to Expedite Development of Novel Products to Prevent and Treat Disease Caused by Ebola